Compare PDC & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDC | LTRN |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | Japan | United States |
| Employees | 20 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7M | 22.2M |
| IPO Year | N/A | 2020 |
| Metric | PDC | LTRN |
|---|---|---|
| Price | $7.10 | $3.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 130.1K | ★ 278.3K |
| Earning Date | 07-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.46 | $1.11 |
| 52 Week High | $8.40 | $5.74 |
| Indicator | PDC | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 48.62 | 66.85 |
| Support Level | $4.48 | $3.04 |
| Resistance Level | $7.90 | $3.09 |
| Average True Range (ATR) | 0.77 | 0.28 |
| MACD | -0.20 | 0.11 |
| Stochastic Oscillator | 39.31 | 84.21 |
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.